QI
CLRB icon

QS Investors’s Cellectar Biosciences CLRB Stock Holding History

QS Investors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$170K Buy
+475
New +$206K ﹤0.01% 1074

Other funds holding CLRB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

QS Investors's CLRB Position: Q2 2021 in Review

QS Investors opened a new position in Cellectar Biosciences (CLRB) in Q2 2021: 475 shares worth $170K. The stake represents ﹤0.01% of the portfolio and ranks #1074 among its holdings.

43 funds tracked by Wall St. Rank hold CLRB as of Q2 2021.

  • QS Investors held 475 shares of Cellectar Biosciences worth $170K as of Q2 2021.
  • Cellectar Biosciences was a new QS Investors position in Q2 2021.
  • Cellectar Biosciences made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1074 holding.
  • 43 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.